New approach to presbyopia treament

Article

This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.

This is the first ESCRS congress for 9-month old company, Technolas, which was formed out of a joint venture between Bausch and Lomb's refractive surgery unit and 20/10 Perfect Vision. The new business was founded to innovate in excimer and femtosecond laser technologies, focusing primarily on the correction of presbyopia.

It promotes a comprehensive service and support structure to provide surgeons with training and applications support to adapt their clinics to service the developing presbyopia patient segment.

CCO Mike Riding explained: “The current LASIK market is very tough. The number of procedures being performed is stuck because 20 to 30 year olds don't have the cash for LASIK. The bread and butter market is very difficult.” Against this background he asks doctors to imagine a new procedure, a minimally invasive technique, that will service 40 to 60 year olds - the baby boomers.

Enter the new INTRACOR femtosecond laser procedure from Technolas. The INTRACOR technique provides flapless intrastromal correction using the FEMTEC femtosecond laser to reshape the cornea. Technolas says this can be achieved whilst still maintaining the integrity of the corneal surface.In addition to offering a solution for presbyopia the technique can also be used as a minimally invasive technique for hyperopia, myopia and astigmatism.

“We believe the market size will be several times larger than the current LASIK market,” said Riding. He explained that this is not just Technolas's view, but a growing belief that demand to treat presbyopia will continue to grow. Strong attendance at the wet labs run by the company at 20-minute intervals during this year's Congress could be evidence that he is right.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.